Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC. Methods: We reviewed radiologically resectable PDAC patients who received resection with curative intent at a tertiary hospital in South Korea between January 2012 and August 2019. A total of 202 patients underwent curative resection for resectable PDAC: 167 underwent surgical resection first during this period, and 35 received neoadjuvant chemotherapy/chemoradiation therapy followed by surgery. Resectable PDAC patients were subdivided, and 1:3 propensity score matching (PSM) was performed to reduce selection bias. Results: Compared with the group that received surgery first, the group that received neoadjuvant treatment followed by surgery had significantly smaller tumors (22.0 mm vs 27.0 mm, p=0.004), a smaller proportion of patients with postoperative pathologic T stage (p=0.026), a smaller proportion of patients with lymphovascular invasion (20.0% vs 40.7%, p=0.022), and a larger proportion of patients with negative resection margins (74.3% vs 51.5%, p=0.049). After PSM, the group that received neoadjuvant therapy had a significantly longer progression-free survival than those in the group that underwent surgery first (29.6 months vs 15.1 months, p=0.002). Overall survival was not significantly different between the two groups after PSM analysis. Conclusions: We observed significantly better surgical outcomes and progression-free survival with the addition of neoadjuvant therapy to the management of resectable PDAC. However, despite PSM, there was still selection bias due to the use of different regimens between the groups receiving surgery first and neoadjuvant therapy. Large homogeneous samples are needed in the future prospective studies.
Abstract
Background/Aims: Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC. Methods: We reviewed radiologically resectable PDAC patients who received resection with curative intent at a tertiary hospital in South Korea between January 2012 and August 2019. A total of 202 patients underwent curative resection for resectable PDAC: 167 underwent surgical resection first during this period, and 35 received neoadjuvant chemotherapy/chemoradiation therapy followed by surgery. Resectable PDAC patients were subdivided, and 1:3 propensity score matching (PSM) was performed to reduce selection bias. Results: Compared with the group that received surgery first, the group that received neoadjuvant treatment followed by surgery had significantly smaller tumors (22.0 mm vs 27.0 mm, p=0.004), a smaller proportion of patients with postoperative pathologic T stage (p=0.026), a smaller proportion of patients with lymphovascular invasion (20.0% vs 40.7%, p=0.022), and a larger proportion of patients with negative resection margins (74.3% vs 51.5%, p=0.049). After PSM, the group that received neoadjuvant therapy had a significantly longer progression-free survival than those in the group that underwent surgery first (29.6 months vs 15.1 months, p=0.002). Overall survival was not significantly different between the two groups after PSM analysis. Conclusions: We observed significantly better surgical outcomes and progression-free survival with the addition of neoadjuvant therapy to the management of resectable PDAC. However, despite PSM, there was still selection bias due to the use of different regimens between the groups receiving surgery first and neoadjuvant therapy. Large homogeneous samples are needed in the future prospective studies.
참고문헌 (31)
- Miller KD, "Cancer treatment and survivorship statistics, 2016", CA Cancer J Clin, 66, pp.271~289 (2016)
- "Cancer stat facts: pancreas cancer"[URL]
- Oettle H, "Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001randomized trial", JAMA, 310, pp.1473~1481 (2013)
- Kurahara H, "A therapeutic strategy for resectable pancreatic cancer based on risk factors of early recurrence", Pancreas, 47, pp.753~758 (2018)
- Nishio K, "Preoperative predictors for early recurrence of resectable pancreatic cancer", World J Surg Oncol, 15, pp.16~ (2017)
- Schwarz L, "Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy : a multicenter, non-comparative, randomized, phase II trial(PANACHE01-PRODIGE48 study)", BMC Cancer, 18, pp.762~ (2018)
- Lee HS, "Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma", J Gastroenterol Hepatol, 35, pp.499~507 (2020)
- Tzeng CW, "Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy", Ann Surg Oncol, 19, pp.2045~2053 (2012)
- Tajima H, "Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer", Mol Clin Oncol, 11, pp.157~166 (2019)
- Petrelli F, "FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer : a meta-analytical review of published studies", Pancreas, 44, pp.515~521 (2015)
- Bakens MJ, "The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals : a nationwide population-based analysis", Cancer Med, 5, pp.2825~2831 (2016)
- Bradley A, "Upfront surgery versus neoadjuvant therapy for resectable pancreatic cancer : systematic review and Bayesian network meta-analysis", Sci Rep, 9, pp.4354~ (2019)
- Motoi F, "Randomized phase II", III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer(Prep-02, Jpn J Clin Oncol, pp.2019, 49[DOI]
- Mokdad AA, "Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer : a propensity score matched analysis", J Clin Oncol, 35, pp.515~522 (2017)
- Ren X, "Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer : a meta-analysis and systematic review", Onco Targets Ther, 12, pp.733~744 (2019)
- RaufiAG, "Neoadjuvant treatment for pancreatic cancer", Semin Oncol, 46, pp.19~27 (2019)
- Blair AB, "A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma", Pancreas, 48, pp.973~984 (2019)
- Datta SK, "Survival outcomes between surgery with adjuvant therapy compared to neoadjuvant therapy with surgery in stage I pancreatic adenocarcinoma : results from a large national cancer database", J Clin Oncol, 37(4 Suppl), pp.335~335 (2019)
- Hashmi A, "Neoadjuvant versus adjuvant chemotherapy for resectable pancreatic adenocarcinoma : a national cancer database analysis", Am Surg, 84, pp.1439~1445 (2018)
- Cho IR, "Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer"in a Korean"population : a single-center cohort study", Semin Oncol, 44, pp.420~427 (2017)
- Versteijne E, "Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer : results of the Dutch randomized phase III PREOPANC Trial", J Clin Oncol, 38, pp.1763~1773 (2020)
- Casadei R, "Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer : a single-center prospective, randomized, controlled trial which failed to achieve accrual targets", J Gastrointest Surg, 19, pp.1802~1812 (2015)
- Fujii T, "Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head : an observational study using inverse probability of treatment weighting", J Gastroenterol, 52, pp.81~93 (2017)
- Ielpo B, "A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma", Surg Oncol, 26, pp.402~410 (2017)
- Suker M, "FOLFIRINOX for locally advanced pancreatic cancer : a systematic review and patient-level meta-analysis", Lancet Oncol, 17, pp.801~810 (2016)
- Zhan HX, "Neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of prospective studies", Cancer Med, 6, pp.1201~1219 (2017)
- Golcher H, "Neoadjuvant chemoradiation therapy with gemcitabine", cisplatin and surgery versus immediate surgery in resectable pancreatic cancer : results of the first prospective randomized phase II trial, 2015, pp.191, 7~16
- Tempero MA, "NCCN guidelines updates : pancreatic cancer", J Natl Compr Canc Netw, 17, pp.603~605 (2019)
- Cloyd JM, "Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma", JAMA Surg, 152, pp.1048~1056 (2017)
- Bissolati M, "Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer", Tumour Biol, 36, pp.991~996 (2015)
- Lee JS, "Liquid biopsy in pancreatic ductal adenocarcinoma : current status of circulating tumor cells and circulating tumor DNA", Mol Oncol, 13, pp.1623~1650 (2019)